Anti-Carbonic Anhydrase 9 (CA9/G250) Rabbit Polyclonal Antibody for WB, ELISA - Q16790

Core Product Specifications and Parameters

Biological Background: Carbonic Anhydrase 9 (CA9/G250) Function and Localization

• CA9, also known as CAIX, MN, or G250, is a transmembrane carbonic anhydrase that catalyzes the reversible hydration of carbon dioxide to bicarbonate and protons, playing a key role in pH homeostasis.
• The protein localizes to the cell membrane, particularly the microvillus membrane, and is also found in the nucleus and nucleolus.
• In normal tissues, expression is highly restricted, with the most abundant levels in gastric mucosa epithelial cells. However, it is frequently overexpressed in carcinoma cell lines, making it a useful tumor-associated marker.
• Post-translational modifications include N-linked glycosylation, phosphorylation, and a disulfide bond, which may influence stability and function.
• The enzyme requires zinc as a cofactor for catalytic activity, characteristic of alpha-carbonic anhydrases.
• Alternative names such as carbonate dehydratase IX, renal cell carcinoma-associated antigen G250, and p54/58N reflect its roles in physiology and oncology.

Experimental Guidance and Technical Tips

• The immunogen covers amino acids 52–151 in the extracellular domain. For Western blot, consider using whole-cell lysates or membrane fractions under reducing conditions to break disulfide bonds.
• ELISA applications may require titration to optimize signal-to-noise ratio. Validate cross-reactivity with mouse and rat samples using appropriate controls.
• Due to restricted expression in normal tissues, detection in tissue lysates may benefit from enrichment steps or use of positive control carcinoma cell lines.
• For applications such as IHC or IF, optimization is recommended because native conformations might mask the epitope recognized by this polyclonal antibody.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio is a strategic sourcing partner for IVD raw materials, supporting diagnostic developers and research institutes with streamlined access to validated reagents. This anti-CA9 antibody targets a key tumor-associated antigen, and our portfolio extends to matched antibody pairs, bulk monoclonal/polyclonal antibodies, and ancillary reagents. From early-stage concept to clinical application, we help you secure rare-target raw materials and technical consultation for your diagnostic programs.